To play this presentation please log in.
Don't have an account?
Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.
Faculty
Carla Casulo
MD
University of Rochester, Wilmot Cancer Institute, Rochester, New York
Associate Professor of Medicine, Division of Hematology/Oncology, Assistant Director, Cancer Research Training and Education
Laurie H Sehn
MD, MPH
BC Cancer Centre for Lymphoid Cancer, Vancouver, British Columbia, Canada
Chair, Lymphoma Tumour Group
University of British Columbia, Vancouver, British Columbia, Canada
Clinical Professor of Medicine, Division of Medical Oncology
Vancouver, British Columbia, Canada
Podcast Editor, Blood
Matthew Matasar
MD
Rutgers Cancer Institute, New Brunswick, New Jersey
Chief, Division of Blood Disorders,
Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey
Hematologist/Oncologist, Professor
TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of follicular lymphoma.
LEARNING OBJECTIVES
- Analyze how age, performance status, prior therapeutic exposure, and other biological and disease-related factors affect the selection and sequencing of therapy for patients with relapsed/refractory (R/R) follicular lymphoma (FL).
- Evaluate published clinical research establishing the efficacy and safety of combined Bruton tyrosine kinase inhibitor/anti-CD20 antibody therapy for R/R FL, and select patients for treatment with available combinations.
- Appreciate the biological rationale for, available data with, and current clinical role of EZH2 inhibitors in treatment for patients with R/R FL, and discern how these agents can be appropriately and safely integrated into contemporary clinical algorithms.
- Recognize the spectrum, frequency and severity of adverse events associated with various therapies commonly used in the care of patients with R/R FL, and consider recommended approaches to prevent, ameliorate and manage resultant side effects.
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and a short post-test, enables the participant to earn up to 1 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.
PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/FLThinkTank2024/3/Video/CME.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
Carla Casulo, MD
Associate Professor of Medicine
Division of Hematology/Oncology
Director, Hematology/Oncology Fellowship Program
University of Rochester
Wilmot Cancer Institute
Rochester, New York
Consulting Agreements and Honoraria: AbbVie Inc, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc; Contracted Research: Genentech, a member of the Roche Group, Gilead Sciences Inc; Nonrelevant Financial Relationships: American Society of Hematology, Lymphoma Research Foundation.
Matthew Matasar, MD
Chief, Division of Blood Disorders
Rutgers Cancer Institute
Hematologist/Oncologist
Professor
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey
Advisory Committees: Allogene Therapeutics, Arvinas, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc, Merck; Consulting Agreements: AbbVie Inc, Genentech, a member of the Roche Group, Novartis, Pfizer Inc, Roche Laboratories Inc; Contracted Research: Genentech, a member of the Roche Group, Janssen Biotech Inc, Pfizer Inc, Roche Laboratories Inc; Honoraria and Stipends: ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Ipsen Biopharmaceuticals Inc, Kite, A Gilead Company, Regeneron Pharmaceuticals Inc; Stock Ownership — Public Companies: Merck.
Laurie H Sehn, MD, MPH
Chair, Lymphoma Tumour Group
BC Cancer Centre for Lymphoid Cancer
Clinical Professor of Medicine
Division of Medical Oncology
University of British Columbia
Podcast Editor, Blood
Vancouver, British Columbia, Canada
Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Novartis, Seagen Inc, Teva Oncology; Contracted Research: Genentech, a member of the Roche Group; Data and Safety Monitoring Board/Committee: CARGO Therapeutics.
EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
These activities are supported by educational grants from Genentech, a member of the Roche Group, Genmab US Inc, Novartis, and Regeneron Pharmaceuticals Inc.
Release date: April 2025
Expiration date: April 2026
After completing the post-test, learners may download and review the answers here in order to identify further areas of study.
Alderuccio JP et al. Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: A single-centre, single-arm, phase 2 trial. Lancet Haematol 2025;12(1):e23-34. Abstract
Alderuccio JP et al. Loncastuximab tesirine with rituximab induces robust and durable complete metabolic responses in high-risk relapsed/refractory follicular lymphoma. ASH 2024;Abstract 337.
Batlevi CL et al. Tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma: Phase 1b results of symphony-1. Blood 2022;140(Supplement 1):2296-8. Abstract
Chavez JC et al. Golcadomide (GOLCA) ± rituximab (RTX) demonstrates durable efficacy and is well tolerated in patients (pts) with relapsed/refractory follicular lymphoma (R/R FL): Updated results from the phase 1/2 CC-99282-NHL-001 study. ASH 2024;Abstract 3018.
Jurczak W et al. Nemtabrutinib, a noncovalent reversible BTK inhibitor in relapsed or refractory follicular lymphoma: Results from the phase 2 Bellwave-003 study. ASH 2024;Abstract 1634.
Morschhauser F et al.Tazemetostat for patients with relapsed or refractory follicular lymphoma: An open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol 2020;21(11):1433-42. Abstract
Salles G et al. Efficacy of subcutaneous epcoritamab vs tisa-cel in R/R LBCL CAR T-naive and CAR T-eligible patients: An indirect comparison. ASH 2023;Abstract 1733.
Sehn LH et al. Tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Results from a phase 3 study (inMIND). ASH 2024;Abstract LBA1.
Trotman J et al. Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the Rosewood study. EHA 2023;Abstract P1080.
Zinzani PL et al. ROSEWOOD: A phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma. J Clin Oncol 2023;41(33):5107-17. Abstract